Host Defense Peptides of Thrombin Modulate Inflammation and Coagulation in Endotoxin-Mediated Shock and Pseudomonas aeruginosa Sepsis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Kalle, Martina ^a   Papareddy, Praveen ^a   Kasetty, Gopinath ^a   Mörgelin, Matthias ^a   van der Plas, Mariena J A ^a   Rydengård, Victoria ^a,c   Malmsten, Martin ^b   Albiger, Barbara ^a,d   Schmidtchen, Artur ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c MEDEON   (Sweden)

^d EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; FIBRIN; GLYCYLLYSYLTYROSYLGLYCYLPHENYLALANYLTYROSYLTHREONYLHISTIDYLVALYLPHENYLAL ANYLARGINYLLEUCYLLYSYLLYSYLTRYPTOPHYLISOLEUCYLGLUTAMINYLLYSYLVALYLISOLEU CYLASPARTYLGLUTAMINYLPHENYLALANYLGLYCYLGLUTAMIC ACID; HISTIDYLVALYLPHENYLALANYLARGINYLLEUCYLLYSYLLYSYLTRYPTOPHYLISOLEUCYLGLUTA MINYLLYSYLVALYLISOLEUCYLASPARTYLGLUTAMINYLPHENYLALANYLGLYCYLGLUTAMIC ACID; LIPOPOLYSACCHARIDE; PEPTIDE DERIVATIVE; THROMBIN; TRYPTOPHYLPHENYLALANYLPHENYLALANYLPHENYLALANYLTYROSYLTYROSYLLEUCYLISOLEU CYLISOLEUCYLGLYCYLGLYCYLGLYCYLVALYLVALYLTHREONYLHISTIDYLGLUTAMINYLGLUTAM INYLARGINYLLYSYLLYSYLLYSYLLYSYLASPARTYLGLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; FIBRIN DEPOSITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG DISEASE; MALE; MORTALITY; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS AERUGINOSA SEPSIS; PSEUDOMONAS INFECTION; RISK REDUCTION; SHOCK;

ANIMALS; BLOOD COAGULATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTOXINS; ESCHERICHIA COLI; FIBRIN; FLOW CYTOMETRY; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; PEPTIDES; PSEUDOMONAS AERUGINOSA; SEPSIS; SHOCK, SEPTIC; THROMBIN;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 84871268218     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051313     Document Type: Article

References (51)

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, et al. (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical care medicine 36: 296-327.
2. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, et al. (2006) Sepsis in European intensive care units: results of the SOAP study. Critical care medicine 34: 344-353.
3. Wittebole X, Castanares-Zapatero D, Laterre PF, (2010) Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm 2010: 568396.
4. Kohler T, van Delden C, (2009) [Pseudomonas aeruginosa infections: from bench to bedside]. Rev Med Suisse 5: 732-734.
5. van Delden C, (2007) Pseudomonas aeruginosa bloodstream infections: how should we treat them? Int J Antimicrob Agents 30 Suppl 1: S71-75.
6. Page MG, Heim J, (2009) Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol 9: 558-565.
7. Bryant CE, Spring DR, Gangloff M, Gay NJ, (2010) The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol 8: 8-14.
8. Hotchkiss RS, Karl IE, (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
9. Rittirsch D, Flierl MA, Ward PA, (2008) Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8: 776-787.
10. de Jong HK, van der Poll T, Wiersinga WJ, (2010) The systemic pro-inflammatory response in sepsis. J Innate Immun 2: 422-430.
11. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, et al. (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185: 5628-5636.
12. Delvaeye M, Conway EM, (2009) Coagulation and innate immune responses: can we view them separately? Blood 114: 2367-2374.
13. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, et al. (2004) Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 103: 1342-1347.
14. Abraham E, (2000) Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Critical care medicine 28: S31-33.
15. Mackman N, (2006) Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis 36: 104-107.
16. Zasloff M, (1992) Antibiotic peptides as mediators of innate immunity. Curr Opin Immunol 4: 3-7.
17. Yeaman MR, Bayer AS, (2006) Antimicrobial peptides versus invasive infections. Curr Top Microbiol Immunol 306: 111-152.
18. Scott MG, Hancock RE, (2000) Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol 20: 407-431.
19. Harder J, Glaser R, Schroder JM, (2007) Human antimicrobial proteins effectors of innate immunity. Journal of endotoxin research 13: 317-338.
20. Hirsch T, Metzig M, Niederbichler A, Steinau HU, Eriksson E, et al. (2008) Role of host defense peptides of the innate immune response in sepsis. Shock 30: 117-126.
21. Lai Y, Gallo RL, (2009) AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 30: 131-141.
22. Elsbach P, (2003) What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses? The Journal of clinical investigation 111: 1643-1645.
23. Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S, (2011) Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 216: 322-333.
24. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, et al. (2010) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 184: 2539-2550.
25. Hancock RE, Sahl HG, (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24: 1551-1557.
26. Papareddy P, Rydengard V, Pasupuleti M, Walse B, Morgelin M, et al. (2010) Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 6: e1000857.
27. Papareddy P, Kalle M, Kasetty G, Morgelin M, Rydengard V, et al. (2010) C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 285: 28387-28398.
28. Oehmcke S, Shannon O, von Kockritz-Blickwede M, Morgelin M, Linder A, et al. (2009) Treatment of invasive streptococcal infection with a peptide derived from human high-molecular weight kininogen. Blood 114: 444-451.
29. Schmidtchen A, Pasupuleti M, Morgelin M, Davoudi M, Alenfall J, et al. (2009) Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J Biol Chem 284: 17584-17594.
30. Levi M, Ten Cate H, (1999) Disseminated intravascular coagulation. N Engl J Med 341: 586-592.
31. Meszaros K, Aberle S, Dedrick R, Machovich R, Horwitz A, et al. (1994) Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein. Blood 83: 2516-2525.
32. Osterud B, (2010) Tissue factor expression in blood cells. Thromb Res 125 Suppl 1: S31-34.
33. Lee KH, Hui KP, Tan WC, (1993) Thrombocytopenia in sepsis: a predictor of mortality in the intensive care unit. Singapore Med J 34: 245-246.
34. Levi M, Meijers JC, (2011) DIC: which laboratory tests are most useful. Blood Rev 25: 33-37.
35. Remick DG, (2007) Pathophysiology of sepsis. Am J Pathol 170: 1435-1444.
36. Lolis E, Bucala R, (2003) Therapeutic approaches to innate immunity: severe sepsis and septic shock. Nat Rev Drug Discov 2: 635-645.
37. Marshall JC, (2010) Endotoxin in the pathogenesis of sepsis. Contrib Nephrol 167: 1-13.
38. Dellinger RP, Vincent JL, Marshall J, Reinhart K, (2008) Important issues in the design and reporting of clinical trials in severe sepsis and acute lung injury. Journal of critical care 23: 493-499.
39. Abraham E, Singer M, (2007) Mechanisms of sepsis-induced organ dysfunction. Critical care medicine 35: 2408-2416.
40. Brown KL, Cosseau C, Gardy JL, Hancock RE, (2007) Complexities of targeting innate immunity to treat infection. Trends Immunol 28: 260-266.
41. Rosenfeld Y, Shai Y, (2006) Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochimica et biophysica acta 1758: 1513-1522.
42. Kasetty G, Papareddy P, Kalle M, Rydengard V, Morgelin M, et al. (2011) Structure-activity studies and therapeutic potential of host defense peptides of human thrombin. Antimicrob Agents Chemother 55: 2880-2890.
43. Kasetty G, Papareddy P, Kalle M, Rydengard V, Walse B, et al. (2011) The C-terminal sequence of several human serine proteases encodes host defense functions. J Innate Immun 3: 471-482.
44. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. Journal of immunology 176: 2455-2464.
45. Semple F, Macpherson H, Webb S, Cox SL, Mallin LJ, et al. (2011) Human beta-defensin 3 affects the activity of pro-inflammatory pathways associated with MyD88 and TRIF. European journal of immunology 41: 3291-3300.
46. Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L, (2002) Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 46: 157-168.
47. Sieprawska-Lupa M, Mydel P, Krawczyk K, Wojcik K, Puklo M, et al. (2004) Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 48: 4673-4679.
48. Couper KN, Blount DG, Riley EM, (2008) IL-10: the master regulator of immunity to infection. Journal of immunology 180: 5771-5777.
49. Castellino FJ, Donahue DL, Navari RM, Ploplis VA, Walsh M, (2011) An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia. Blood 117: 283-289.
50. Herwald H, Morgelin M, Olsen A, Rhen M, Dahlback B, et al. (1998) Activation of the contact-phase system on bacterial surfaces-a clue to serious complications in infectious diseases. Nat Med 4: 298-302.
51. Oehmcke S, Herwald H, (2010) Contact system activation in severe infectious diseases. J Mol Med (Berl) 88: 121-126.